QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

$46.26
-0.87 (-1.85%)
(As of 09/28/2023 ET)
Compare
Today's Range
$46.03
▼
$47.20
50-Day Range
$38.50
▼
$47.13
52-Week Range
$32.69
▼
$47.74
Volume
1.97 million shs
Average Volume
1.05 million shs
Market Capitalization
$6.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Ionis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
4.0% Upside
$48.10 Price Target
Short Interest
Bearish
6.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.71mentions of Ionis Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$964,242 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.35) to ($3.56) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.18 out of 5 stars

Medical Sector

951st out of 969 stocks

Pharmaceutical Preparations Industry

446th out of 455 stocks

See Top Rated MarketRank™ Stocks Here

IONS stock logo

About Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

IONS Price History

IONS Stock News Headlines

September 28, 2023 | finance.yahoo.com
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
September 28, 2023 | finance.yahoo.com
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
September 28, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 28, 2023 | americanbankingnews.com
Morgan Stanley Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00
September 27, 2023 | msn.com
Ionis' metabolic disorder drug lowers high levels of a type of fat in study
September 27, 2023 | finance.yahoo.com
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?
September 27, 2023 | finance.yahoo.com
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
September 27, 2023 | finance.yahoo.com
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
September 28, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 26, 2023 | msn.com
Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
September 26, 2023 | msn.com
Ionis late-stage rare disease data fails to impress Bernstein
September 26, 2023 | finance.yahoo.com
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
September 26, 2023 | reuters.com
Ionis Pharma's genetic disorder drug succeeds in late-stage study
September 26, 2023 | markets.businessinsider.com
Ionis Reports Positive Results From Phase 3 Study Of Olezarsen In Familial Chylomicronemia Syndrome
September 26, 2023 | reuters.com
Ionis Pharma's genetic disorder drug meets main goal in late-stage study
September 26, 2023 | finance.yahoo.com
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
September 26, 2023 | finance.yahoo.com
UPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in study
September 21, 2023 | americanbankingnews.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Hold" by Analysts
September 21, 2023 | americanbankingnews.com
Leerink Partnrs Comments on Ionis Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:IONS)
September 20, 2023 | finance.yahoo.com
Ionis to host investor and analyst day event
September 8, 2023 | finance.yahoo.com
Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?
August 11, 2023 | finance.yahoo.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call Transcript
August 10, 2023 | markets.businessinsider.com
Barclays Remains a Hold on Ionis Pharmaceuticals (IONS)
August 10, 2023 | msn.com
Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)
August 10, 2023 | finance.yahoo.com
Q2 2023 Ionis Pharmaceuticals Inc Earnings Call
August 9, 2023 | finance.yahoo.com
Ionis reports second quarter 2023 financial results
August 3, 2023 | seekingalpha.com
Novartis and Ionis in pact for new cardiovascular therapy
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Company Calendar

Last Earnings
8/09/2023
Today
9/28/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
CIK
874015
Web
www.ionispharma.com
Phone
(760) 931-9200
Fax
760-603-2700
Employees
796
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.10
High Stock Price Forecast
$67.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+2.9%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-269,720,000.00
Net Margins
-48.81%
Pretax Margin
-44.60%
Return on Equity
-59.17%
Return on Assets
-11.40%

Debt

Debt-to-Equity Ratio
3.07
Current Ratio
9.09
Quick Ratio
9.00

Sales & Book Value

Annual Sales
$587 million
Price / Sales
11.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.03 per share
Price / Book
11.60

Miscellaneous

Outstanding Shares
143,330,000
Free Float
139,528,000
Market Cap
$6.70 billion
Optionable
Optionable
Beta
0.51
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Brett P. Monia Ph.D. (Age 62)
    Founder, CEO & Director
    Comp: $1.71M
  • Ms. Elizabeth L. Hougen M.A.Ms. Elizabeth L. Hougen M.A. (Age 61)
    M.B.A., M.S., Exec. VP of Fin. & CFO
    Comp: $1.02M
  • Ms. Onaiza Cadoret-Manier M.A. (Age 58)
    M.B.A., M.S., Exec. VP, Chief Global Product Strategy & Operations Officer
    Comp: $930.82k
  • Ms. B. Lynne Parshall Esq.Ms. B. Lynne Parshall Esq. (Age 69)
    J.D., Sr. Strategic Advisor & Director
    Comp: $334.64k
  • Dr. Richard S. Geary Ph.D. (Age 65)
    Exec. VP & Chief Devel. Officer
    Comp: $946.26k
  • Mr. Joseph T. Baroldi M.A. (Age 44)
    M.B.A., M.S., Exec. VP & Chief Bus. Officer
    Comp: $815.87k
  • Mr. Darren Gonzales
    Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett BSc (Age 66)
    Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. D. Wade Walke Ph.D.
    Sr. VP of Investor Relations
  • Mr. Patrick R. O'Neil Esq. (Age 49)
    Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IONS Stock - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price forecast for 2023?

9 equities research analysts have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $67.00. On average, they predict the company's share price to reach $48.10 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2023?

Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS shares have increased by 23.8% and is now trading at $46.75.
View the best growth stocks for 2023 here.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our IONS earnings forecast.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings data on Wednesday, August, 9th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $1.54. The firm earned $188 million during the quarter, compared to analysts' expectations of $136.84 million. Ionis Pharmaceuticals had a negative net margin of 48.81% and a negative trailing twelve-month return on equity of 59.17%.

What ETFs hold Ionis Pharmaceuticals' stock?

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT).

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $586.28 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Bellevue Group AG (6.54%), Clearbridge Investments LLC (3.62%), BVF Inc. IL (1.99%), Camber Capital Management LP (1.74%), ARK Investment Management LLC (1.69%) and Geode Capital Management LLC (1.51%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $46.75.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $6.70 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

The company employs 796 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.

This page (NASDAQ:IONS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -